Trinity Biotech (NASDAQ:TRIB) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Trinity Biotech (NASDAQ:TRIB) in a research note issued on Tuesday. The firm set a “sell” rating on the stock.

Trinity Biotech Trading Down 0.0 %

NASDAQ TRIB opened at $0.58 on Tuesday. The stock has a market cap of $10.47 million, a price-to-earnings ratio of -0.26 and a beta of 1.21. Trinity Biotech has a 12 month low of $0.48 and a 12 month high of $3.55. The company’s 50 day moving average is $0.68 and its two-hundred day moving average is $1.02.

Institutional Investors Weigh In On Trinity Biotech

A hedge fund recently raised its stake in Trinity Biotech stock. Hunter Associates Investment Management LLC lifted its holdings in Trinity Biotech plc (NASDAQ:TRIB) by 5.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 378,590 shares of the company’s stock after acquiring an additional 18,780 shares during the period. Hunter Associates Investment Management LLC’s holdings in Trinity Biotech were worth $334,000 at the end of the most recent reporting period. 78.97% of the stock is owned by institutional investors.

About Trinity Biotech

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.